TransMedics Group Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	605.49	441.54	241.62	93.46	30.26
Revenue Growth (YoY)	37.13%	82.74%	158.53%	208.83%	18.03%
Cost of Revenue	242.69	179.46	87.53	28.19	9.1
Gross Profit	362.81	262.08	154.09	65.27	21.16
Selling, General & Admin	185.17	168.62	119.55	69.9	38.28
Research & Development	69.06	55.97	27.21	26.81	22.3
Operating Income	108.58	37.5	-28.73	-31.44	-39.43
Interest Income	12.72	12.69	12.85	-1	-0.88
Interest Expense	-13.78	-14.41	-10.79	-3.73	-3.87
Total Non-Operating Income (Expense)	-1.06	-1.72	2.06	-4.73	-4.75
Pretax Income	107.52	35.78	-26.67	-36.17	-44.18
Provision for Income Taxes	82.77	-0.32	1.64	-0.07	-0.04
Net Income	190.29	35.46	-25.03	-36.23	-44.22
Net Income to Common	190.29	35.46	-25.03	-36.23	-44.22
Net Income Growth	436.58%	-	-	-	-
Shares Outstanding (Basic)	34	33	33	30	28
Shares Outstanding (Diluted)	41	35	33	30	28
Shares Change (YoY)	15.12%	8.30%	10.02%	7.02%	11.80%
EPS (Basic)	5.60	1.07	-0.77	-1.23	-1.60
EPS (Diluted)	4.87	1.01	-0.77	-1.23	-1.60
EPS Growth	382.18%	-	-	-	-
Free Cash Flow	133.59	-80.94	-164.88	-57.72	-32.38
Free Cash Flow Per Share	3.30	-2.30	-5.07	-1.95	-1.17
Gross Margin	59.92%	59.36%	63.77%	69.84%	69.92%
Operating Margin	17.93%	8.49%	-11.89%	-33.64%	-130.29%
Profit Margin	31.43%	8.03%	-10.36%	-38.77%	-146.11%
FCF Margin	22.06%	-18.33%	-68.24%	-61.76%	-107.01%
EBITDA	135.77	57.25	-20.55	-27.96	-37.61
EBITDA Margin	22.42%	12.97%	-8.50%	-29.92%	-124.28%
EBIT	108.58	37.5	-28.73	-31.44	-39.43
EBIT Margin	17.93%	8.49%	-11.89%	-33.64%	-130.29%
Effective Tax Rate	76.98%	-0.88%	-6.16%	0.18%	0.08%

Updated Dec 31, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.